| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018923769 |
| P356 | DOI | 10.1023/A:1005568406664 |
| P698 | PubMed publication ID | 10961720 |
| P50 | author | Gino R Corazza | Q57090014 |
| P2093 | author name string | F Trevisani | |
| G Gasbarrini | |||
| M Bernardi | |||
| M Di Stefano | |||
| L Cecchetti | |||
| S De Notariis | |||
| L Minguzzi | |||
| G Veneto | |||
| P2860 | cites work | Transection of the oesophagus for bleeding oesophageal varices | Q34211834 |
| Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice | Q34223451 | ||
| Osteoporosis and skeletal fractures in chronic liver disease | Q34391773 | ||
| Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels | Q34538717 | ||
| Peripheral bone mineral content in patients with fatty liver and hepatic cirrhosis | Q34568126 | ||
| Bone loss after orthotopic liver transplantation | Q36728610 | ||
| Bone changes in alcoholic liver cirrhosis. A histomorphometrical analysis of 52 cases | Q39518231 | ||
| Severe Osteoporosis in Men | Q40462166 | ||
| Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis | Q40565765 | ||
| Prevalence and prediction of osteopenia in chronic liver disease | Q41186600 | ||
| Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. | Q41326206 | ||
| Biochemical markers in the assessment of bone disease | Q41647553 | ||
| Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. | Q44025886 | ||
| Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen | Q44363159 | ||
| Bone disease in alcohol abuse. | Q45948220 | ||
| Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. | Q50970251 | ||
| Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. | Q51650453 | ||
| Ethanol reduces bone formation and may cause osteoporosis. | Q51755941 | ||
| Bone loss after liver transplantation. | Q52441112 | ||
| Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. | Q54104714 | ||
| Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. | Q55060873 | ||
| Glucocorticoid-Induced Osteoporosis: Pathogenesis and Management | Q60530953 | ||
| Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women | Q67967028 | ||
| Bone mineral density and abstention-induced changes in bone and mineral metabolism in noncirrhotic male alcoholics | Q67967186 | ||
| Circulating osteocalcin during oral anticoagulant therapy | Q68099654 | ||
| Bone disease after orthotopic liver transplantation | Q68128457 | ||
| Serum levels of cytokines in chronic liver diseases | Q68169595 | ||
| Factors influencing the development of metabolic bone disease in primary biliary cirrhosis | Q68573003 | ||
| Bone Gla protein (osteocalcin) assay standardization report | Q68720829 | ||
| High total and free 1,25-dihydroxyvitamin D concentrations in serum of premature infants | Q68734561 | ||
| Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids | Q68903834 | ||
| Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease | Q69734919 | ||
| Osteocalcin in human serum: a circadian rhythm | Q69865344 | ||
| Impaired carboxylation of osteocalcin in warfarin-treated patients | Q69890304 | ||
| Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer | Q70598693 | ||
| Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation | Q70658036 | ||
| Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis | Q70813061 | ||
| Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D | Q71129361 | ||
| Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia | Q71259493 | ||
| Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH) | Q72069973 | ||
| Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D | Q72107442 | ||
| Carboxyterminal propeptide of type I procollagen in osteomalacia | Q72788814 | ||
| The diagnosis of osteoporosis | Q72846752 | ||
| Determination of the hepatic elimination capacity (Lm) of galactose by single injection | Q72900504 | ||
| Bone mineral status in end-stage liver disease and the effect of liver transplantation | Q73118499 | ||
| Bone loss and reduced osteoblast function in primary biliary cirrhosis | Q93642995 | ||
| P433 | issue | 7 | |
| P921 | main subject | viral hepatitis | Q1983841 |
| liver cirrhosis | Q147778 | ||
| P304 | page(s) | 1392-1399 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis | |
| P478 | volume | 45 |
| Q37741812 | 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients |
| Q93079405 | Bone Diseases in Patients with Chronic Liver Disease |
| Q36496861 | Bone disorders in experimentally induced liver disease in growing rats |
| Q37275718 | Bone mineral density and disorders of mineral metabolism in chronic liver disease |
| Q33260701 | Bone mineral density in children with cirrhosis. |
| Q35060640 | Bone mineral density measurements, bone markers and serum vitamin D concentrations in men with chronic non-cirrhotic untreated hepatitis C. |
| Q33691692 | Chronic non-cholestatic liver disease is not associated with an increased fracture rate in children. |
| Q64057046 | Crosssectional Assessment of Bone Mass Density in Adults with Hepatitis B Virus and Hepatitis C Virus Infection |
| Q37625814 | Current understanding of osteoporosis associated with liver disease |
| Q38911526 | Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. |
| Q35046555 | Metabolic bone disease in patients with liver disease |
| Q44637688 | Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem |
| Q26824690 | Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications |
| Q36263107 | Pegylated interferon α/ribavirin therapy enhances bone mineral density in children with chronic genotype 4 HCV infection |
| Q33813357 | Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats |
| Q84190139 | Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients |
| Q37673471 | Serum sclerostin in hepatitis C virus infected patients |
| Q93007197 | The 25(OH)Vitamin D Status Affected the Effectiveness of Oligo Fucoidan in Patients with Chronic Hepatitis B Virus Infection with Immune Tolerance Phase |
| Q36316676 | Theoretical basis of a beneficial role for vitamin D in viral hepatitis |
| Q33722412 | Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men |
Search more.